Figure 6.

RO suppresses the growth of prostate cancer cell xenografts in vivo but does not affect animal weight.

Notes: (A) RO suppresses the growth of PC-3 prostate cancer cell xenografts in vivo. PC-3 cells (5×10⁶ in 0.15 mL solution) were mixed with matrigel and RPMI-1640 medium (1/1, v/v) and injected subcutaneously into both flanks of 6-week-old male athymic nu/nu nude mice. Tumors were allowed to develop and tumor volume monitored. When tumor volume reached ~100 mm³, the animals were randomly assigned to three groups (n=6/group). RO was administered by tail vein injection, beginning with 5 or 20 mg/kg/d for 5 days (loading dose), followed by the same dosing every other day for six additional treatments, followed by a final injection 2 hours before sacrifice, as indicated by the arrows in the figure. Animals in the control group received the vehicle alone under identical conditions. ^*Significantly different from control group (P<0.05, ANOVA). (B) RO is nontoxic to tumor-bearing nude mice. Animal weights were monitored throughout the experiment, as shown in A. No significant differences in animal weights were observed between control animals and those treated with RO. (C) Representative tumor images from the experiment are described in A. Tumors were photographed at the end of the experiment. Two out of 12 tumors in the 20 mg/kg RO group were completely eradicated, as shown in the two right hand images in the bottom row.

Abbreviations: ANOVA, analysis of variance; RO, 4′-(6-[allylmethylamino]hexyloxy)-4-bromo-2′-fluorobenzophenone fumarate; RPMI-1640 medium, Roswell Park Memorial Institute 1640 medium.